A phase I/II trial (NCT03767582) is investigating the safety of nivolumab in combination with BMS-813160 (a CCR2/CCR5 dual antagonist) and GVAX (pancreatic cancer vaccine) in locally advanced pancreatic cancer patients. This evidence concerns the gene CCR5 and familial pancreatic carcinoma.